Since the advent of Prostate-Specific Antigen (PSA) screening, the PCa detection rate has increased dramatically, with the majority of the cases being low-risk cases, with better outcomes and minimal side effects when prompt, appropriate treatment is applied [2,3]. The gene discussed is KLK3; the disease is posterior cortical atrophy.